dostęp otwarty

Tom 15, Nr 4 (2019)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2020-01-28
Pobierz cytowanie

Leczenie i postępowanie objawowe w stwardnieniu rozsianym Rekomendacje Sekcji SM i Neuroimmunologii Polskiego Towarzystwa Neurologicznego

Beata Zakrzewska-Pniewska, Monika Adamczyk-Sowa, Waldemar Brola, Alicja Kalinowska, Alina Kułakowska, Jacek Losy, Dagmara Mirowska-Guzel, Andrzej Potemkowski, Konrad Rejdak, Iwona Sarzyńska-Długosz, Małgorzata Siger, Jacek Zaborski, Halina Bartosik-Psujek
DOI: 10.5603/PPN.2019.0033
·
Pol. Przegl. Neurol 2019;15(4):191-217.

dostęp otwarty

Tom 15, Nr 4 (2019)
Rekomendacje i zalecenia ekspertów
Opublikowany online: 2020-01-28

Streszczenie

Zespół ekspertów Polskiego Towarzystwa Neurologicznego opracował zasady postępowania w leczeniu poszczególnych objawów występujących u pacjentów ze stwardnieniem rozsianym. Rekomendacje opracowano na podstawie wyników najnowszych badań klinicznych, zaleceń zagranicznych towarzystw naukowych oraz własnego doświadczenia klinicznego autorów. Omówiono postępowanie w spastyczności, ataksji i drżeniu, zespole zmęczenia, w przypadku zaburzeń zwieraczy dróg moczowych i przewodu pokarmowego, zaburzeń seksualnych oraz w zespołach bólowych występujących typowo w stwardnieniu rozsianym. Przedstawiono również zasady postępowania w przypadku zaburzeń psychicznych i zaburzeń funkcji poznawczych. W dokumencie podsumowano możliwości terapii objawowej w stwardnieniu rozsianym w warunkach polskich.

Streszczenie

Zespół ekspertów Polskiego Towarzystwa Neurologicznego opracował zasady postępowania w leczeniu poszczególnych objawów występujących u pacjentów ze stwardnieniem rozsianym. Rekomendacje opracowano na podstawie wyników najnowszych badań klinicznych, zaleceń zagranicznych towarzystw naukowych oraz własnego doświadczenia klinicznego autorów. Omówiono postępowanie w spastyczności, ataksji i drżeniu, zespole zmęczenia, w przypadku zaburzeń zwieraczy dróg moczowych i przewodu pokarmowego, zaburzeń seksualnych oraz w zespołach bólowych występujących typowo w stwardnieniu rozsianym. Przedstawiono również zasady postępowania w przypadku zaburzeń psychicznych i zaburzeń funkcji poznawczych. W dokumencie podsumowano możliwości terapii objawowej w stwardnieniu rozsianym w warunkach polskich.

Pobierz cytowanie

Słowa kluczowe

rekomendacje, leczenie objawowe, stwardnienie rozsiane

Informacje o artykule
Tytuł

Leczenie i postępowanie objawowe w stwardnieniu rozsianym Rekomendacje Sekcji SM i Neuroimmunologii Polskiego Towarzystwa Neurologicznego

Czasopismo

Polski Przegląd Neurologiczny

Numer

Tom 15, Nr 4 (2019)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

191-217

Data publikacji on-line

2020-01-28

DOI

10.5603/PPN.2019.0033

Rekord bibliograficzny

Pol. Przegl. Neurol 2019;15(4):191-217.

Słowa kluczowe

rekomendacje
leczenie objawowe
stwardnienie rozsiane

Autorzy

Beata Zakrzewska-Pniewska
Monika Adamczyk-Sowa
Waldemar Brola
Alicja Kalinowska
Alina Kułakowska
Jacek Losy
Dagmara Mirowska-Guzel
Andrzej Potemkowski
Konrad Rejdak
Iwona Sarzyńska-Długosz
Małgorzata Siger
Jacek Zaborski
Halina Bartosik-Psujek

Referencje (122)
  1. Lance JW. Spasticity: disordered motor control. In: Feldman RG, Young RR, Koella WP. ed. Symposium Synopsis. Year Book Medical Publishers, Chicago 1980: 485–494.
  2. Henze T, Feneberg W, Flachenecker P, et al. [What is new in symptomatic MS treatment: part 2-gait disorder and spasticity] [Article in German]. Nervenarzt. 2017; 88(12): 1428–1434.
  3. Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004; 10(5): 589–595.
  4. Smith CR, LaRocca NG, Giesser BS, et al. High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology. 1991; 41(11): 1829–1831.
  5. Ward AB. Long-term modification of spasticity. J Rehabil Med. 2003(41 Suppl): 60–65.
  6. Platz T, Eickhof C, Nuyens G, et al. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil. 2005; 27(1–2): 7–18.
  7. Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spasticity. Disabil Rehabil. 2006; 28(15): 899–907.
  8. Priebe MM, Sherwood AM, Thornby JI, et al. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil. 1996; 77(7): 713–716.
  9. Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain. 2006; 129(Pt 1): 224–234.
  10. Ward A, Wissel J, Borg J, et al. Functional goal achievement in post-stroke spasticity patients: The BOTOX® Economic Spasticity Trial (BEST). J Rehabil Med. 2014; 46(6): 504–513.
  11. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines RCP, London 2009.
  12. Henze T, Rieckmann P, Toyka KV, et al. Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006; 56(2): 78–105.
  13. Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013; 13(12 Suppl): 55–59.
  14. Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. Handb Clin Neurol. 2014; 122: 513–562.
  15. Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016; 22(11): 1386–1396.
  16. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 2010; 9(12): 1182–1199.
  17. MS Council for Clinical Practical Guidelines. Spasticity management in multiple sclerosis. J Spinal Cord Med. 2005; 28: 167–200.
  18. Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. In: Goodin DD, Ciccarelli O, Thompson A. ed. Handbook of clinical neurology. Vol. 22 (3rd series). Multiple sclerosis and related disorders. Elsevier, Philadelpia 2014: 518–520.
  19. The morbidity of multiple sclerosis. Q J Med. 1992; 83(1): 325–337.
  20. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. 2007(1): CD005029.
  21. Ghez C, Thach WT. The cerebellum. Principles of neural science. 4th edition. McGraw Hill, New York 2000.
  22. Koch M, Mostert J, Heersema D, et al. Tremor in multiple sclerosis. J Neurol. 2007; 254(2): 133–145.
  23. Alusi SH, Worthington J, Glickman S, et al. A study of tremor in multiple sclerosis. Brain. 2001; 124(Pt 4): 720–730.
  24. Pittock SJ, McClelland RL, Mayr WT, et al. Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord. 2004; 19(12): 1482–1485.
  25. Wilkins A, Kemp K, Redondo J, et al. Oxidative injury in multiple sclerosis cerebellar grey matter. Brain Res. 2016; 1642: 452–460.
  26. Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci. 1997; 145(2): 205–211.
  27. Henze T, Feneberg W, Flachenecker P, et al. [What is new in symptomatic MS treatment: part 1-introduction and methodical approach, ataxia and tremor] [Article in German]. Nervenarzt. 2017; 88(12): 1421–1427.
  28. Schapiro RT. Managing the symptoms of multiple sclerosis. 4th edition. Demos, New York 204: 46–51.
  29. Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol. 1984; 41(3): 280–281.
  30. Sechi GP, Zuddas M, Piredda M, et al. Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up. Neurology. 1989; 39(8): 1113–1115.
  31. Naderi F, Javadi SA, Motamedi M, et al. The efficacy of primidone in reducing severe cerebellar tremors in patients with multiple sclerosis. Clin Neuropharmacol. 2012; 35(5): 224–226.
  32. Schroeder A, Linker RA, Lukas C, et al. Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report. Clin Neuropharmacol. 2010; 33(6): 317–318.
  33. Sechi G, Agnetti V, Sulas FMI, et al. Effects of topiramate in patients with cerebellar tremor. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(6): 1023–1027.
  34. Trelles L, Trelles JO, Castro C, et al. Successful treatment of two cases of intention tremor with clonazepam. Ann Neurol. 1984; 16(5): 621.
  35. Bittar RG, Hyam J, Nandi D, et al. Thalamotomy versus thalamic stimulation for multiple sclerosis tremor. J Clin Neurosci. 2005; 12(6): 638–642.
  36. Schuurman PR, Bosch DA, Merkus MP, et al. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord. 2008; 23(8): 1146–1153.
  37. Timmermann L, Deuschl G, Fogel W, et al. Deep Brain Stimulation Association. [Deep brain stimulation for tremor in multiple sclerosis: consensus recommendations of the German Deep Brain Stimulation Association] [Article in German]. Nervenarzt. 2009; 80(6): 673–677.
  38. Giovanni G. Multiple sclerosis related fatigue. J Neurol Neurosurg Psychiatry. 2006; 77: 2–5.
  39. Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010; 33(8): 1061–1067.
  40. Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res. 2004; 56(2): 157–170.
  41. Brola W, Ziomek M, Czernicki J. Zmęczenie w przewlekłych chorobach neurologicznych. Neurol Neurochir Pol. 2007; 41: 340–349.
  42. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci. 2002; 205(1): 51–58.
  43. Merkelbach S, Sittinger H, Koenig J. Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis? J Nerv Ment Dis. 2002; 190(6): 388–393.
  44. Schapiro RT, Schapiro RT, Schapiro RT. Medications used in the treatment of multiple sclerosis. Phys Med Rehabil Clin N Am. 1999; 10(2): 437–46, ix.
  45. Iriarte J, Katsamakis G, de Castro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult Scler. 1999; 5(1): 10–16.
  46. Veauthier C, Hasselmann H, Gold SM, et al. The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA J. 2016; 7: 25.
  47. Achiron A, Givon U, Magalashvili D, et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Mult Scler. 2015; 21(6): 767–775.
  48. Allart E, Benoit A, Blanchard-Dauphin A, et al. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015; 262(8): 1936–1945.
  49. Beckerman H, Blikman LJm, Heine M, et al. TREFAMS-ACE study group. The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme. Trials. 2013; 14: 250.
  50. Betts CD. Bladder and sexual dysfunction in multiple sclerosis. In: Fowler CJ. ed. Neurology of bladder, bowel, and sexual dysfunction: blue books of practical neurology. Butterworth-Heinemann, Boston 1999: 289–308.
  51. Goodwin RJ, Fowler CG. Bladder, bowel and sexual dysfunction: recent advances. In: Thompson AJ, Polman CH, Hohlfeld R. ed. Multiple sclerosis: clinical challenges and controversies. Martin Dunitz, London 1997: 265–281.
  52. Kalsi V, Fowler CJ. Therapy Insight: bladder dysfunction associated with multiple sclerosis. Nat Clin Pract Urol. 2005; 2(10): 492–501.
  53. Araki I, Matsui M, Ozawa K, et al. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol. 2003; 169(4): 1384–1387.
  54. Birder L, de Groat W, Mills I, et al. Neural control of the lower urinary tract: peripheral and spinal mechanisms. Neurourol Urodyn. 2010; 29(1): 128–139.
  55. Pannek J, Blok B, Castro-Diaz D, et al. ed. Guidelines on neurogenic lower tract dysfunction. European Association of Urology 2013. https://uroweb.org/wp-content/uploads/20_Neurogenic-LUTD_LR.pdf (22.11.2019).
  56. Markowitz C. Symptomatic therapy of multiple sclerosis. Continuum (Minneap Minn). 2010; 16(5 Multiple Sclerosis): 90–104.
  57. Bigi S, Yeh E. Symptomatic treatment in multiple sclerosis. US Neurology. 2013; 09(01): 35.
  58. Fowler CJ, van Kerrebroeck PE, Nordenbo A, et al. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis). J Neurol Neurosurg Psychiatry. 1992; 55(11): 986–989.
  59. Kaplan SA, Goldfischer ER, Steers WD, et al. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male. 2010; 13(2): 100–107.
  60. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008; 62(11): 1792–1800.
  61. Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016; 54(1): 78–82.
  62. Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol. 2003; 170(5): 1908–1912.
  63. Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev. 2013(11): CD004375.
  64. Khan S, Game X, Kalsi V, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007; 62(5): 452–457.
  65. El Yazami Adli O, Crocos J. Botulinum neurotoxin — a treatment of lower urinary tract symptoms in multiple sclerosis. Can Urol Assoc J. 2014; 8(1–2): E61–E67.
  66. Gabay B, Maucort-Boulch D, Ruffion A, et al. [Long-term outcomes of intradetrusor botulinum toxin A in multiple sclerosis patients] [Article in French]. Prog Urol. 2019; 29(3): 156–165.
  67. Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology. 1990; 98(6): 1538–1542.
  68. Munteis E, Andreu M, Téllez MJ, et al. Anorectal dysfunction in multiple sclerosis. Mult Scler. 2006; 12(2): 215–218.
  69. Preziosi G, Gordon-Dixon A, Emmanuel A. Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies. Degener Neurol Neuromuscul Dis. 2018; 8: 79–90.
  70. Preziosi G, Raptis DA, Raeburn A, et al. Gut dysfunction in patients with multiple sclerosis and the role of spinal cord involvement in the disease. Eur J Gastroenterol Hepatol. 2013; 25(9): 1044–1050.
  71. Thiruppathy K, Preziosi G. Multiple sclerosis related bowel dysfunction: pathophysiology, clinical manifestation and management. J Neurol Neurophysiol. 2014; 05(06).
  72. Wiesel PH, Norton C, Glickman S, et al. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol. 2001; 13(4): 441–448.
  73. Preziosi G, Raptis DA, Storrie J, et al. Bowel biofeedback treatment in patients with multiple sclerosis and bowel symptoms. Dis Colon Rectum. 2011; 54(9): 1114–1121.
  74. Betts CD, Jones SJ, Fowler CG, et al. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain. 1994; 117 ( Pt 6): 1303–1310.
  75. Fletcher SG, Castro-Borrero W, Remington G, et al. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol. 2009; 6(2): 96–107.
  76. Zorzon M, Zivadinov R, Bosco A, et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler. 1999; 5(6): 418–427.
  77. Fraser C, Mahoney J, McGurl J. Correlates of sexual dysfunction in men and women with multiple sclerosis. J Neurosci Nurs. 2008; 40(5): 312–317.
  78. Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother. 2009; 9(3): 341–350.
  79. O’Connor AB, Schwid SR, Herrmann DN, et al. associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008; 137: 96–111.
  80. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis — prevalence and clinical characteristics. Eur J Pain. 2005; 9(5): 531–542.
  81. Truini A, Galeotti F, Cruccu G. Treating pain in multiple sclerosis. Expert Opin Pharmacother. 2011; 12(15): 2355–2368.
  82. Ehde DM, Osborne TL, Hanley MA, et al. Chronic pain in persons with multiple sclerosis. Phys Med Rehabil Clin N Am. 2005; 16(2): 503–512.
  83. Malec-Milewska M. Ból u chorych na stwardnienie rozsiane. Med Paliat Prakt. 2014; 8: 29–40.
  84. Cruccu G, Biasiotta A, Di Rezze S, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009; 143(3): 186–191.
  85. Finnerup NB, Gottrup H, Jensen TS. Anticonvulsants in central pain. Expert Opin Pharmacother. 2002; 3(10): 1411–1420.
  86. Solaro C, Uccelli MM. Management of pain in multiple sclerosis: a pharmacological approach. Nat Rev Neurol. 2011; 7(9): 519–527.
  87. Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005; 11(4): 398–402.
  88. Truini A, Barbanti P, Pozzilli C, et al. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013; 260(2): 351–367.
  89. Miller L, Mattison P, Paul L, et al. The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler. 2007; 13(4): 527–533.
  90. Brola W, Mitosek-Szewczyk K, Opara J. Symptomatology and pathogenesis of different types of pain in multiple sclerosis. Neurol Neurochir Pol. 2014; 48(4): 272–279.
  91. D'Amico D, La Mantia L, Rigamonti A, et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia. 2004; 24(11): 980–984.
  92. Putzki N, Pfriem A, Limmroth V, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol. 2009; 16(2): 262–267.
  93. Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol. 2008; 126(7): 994–995.
  94. Wissel J, Müller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage. 2000; 20(1): 44–49.
  95. Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs. 2011; 25(3): 187–201.
  96. Modestowicz R, Sosnowski P, Wender M, et al. Morfologia ognisk demielinizacyjnych a zaburzenia funkcji poznawczych i emocjonalnych u chorych na stwardnienie rozsiane. Neurol Neurochir Pol. 2000; 34: 23–34.
  97. Zakrzewska-Pniewska B. Zaburzenia funkcji poznawczych w stwardnieniu rozsianym. In: Szczudlik A, Liberski PP, Barcikowska M. ed. Otępienie. Wydawnictwo UJ, Kraków 2004.
  98. Kurkowska-Jastrzębska I, Mirowska-Guzel D. Zaburzenia poznawcze w stwardnieniu rozsianym i możliwości terapii. Pol Przeg Neurol. 2008; 4(Suppl A): 52–53.
  99. Julian LJ, Julian LJ, Arnett PA, et al. Cognitive predictors of response to treatment for depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2006; 18(3): 356–363.
  100. Kalb R, Beier M, Benedict RHb, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. 2018; 24(13): 1665–1680.
  101. Huijbregts SCJ, Kalkers NF, de Sonneville LMJ, et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology. 2004; 63(2): 335–339.
  102. Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci. 2006; 245(1-2): 41–46.
  103. Gaudino EA, Chiaravalloti ND, DeLuca J, et al. A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis. Neuropsychiatry Neuropsychol Behav Neurol. 2001; 14(1): 32–44.
  104. Smestad C, Sandvik L, Landrø NI, et al. Cognitive impairment after three decades of multiple sclerosis. Eur J Neurol. 2010; 17(3): 499–505.
  105. Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 2010; 74(Suppl 3): S8–15.
  106. Bakirtzis C, Ioannidis P, Messinis L, et al. The rationale for monitoring cognitive function in multiple sclerosis: practical issues for clinicians. Open Neurol J. 2018; 12(1): 31–40.
  107. Filippi M. Cortical reorganisation in patients with MS. J Neurol Neurosurg Psychiatry. 2004; 75(8): 1087–1089.
  108. Wishart HA, Saykin AJ, McDonald BC, et al. Brain activation patterns associated with working memory in relapsing-remitting MS. Neurology. 2004; 62(2): 234–238.
  109. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008; 7(12): 1139–1151.
  110. Sumowski JF, Benedict R, Enzinger C, et al. Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology. 2018; 90(6): 278–288.
  111. Weinstein A, Schwid SR, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol. 1999; 56(3): 319–324.
  112. Kappos L, Freedman M, Polman C, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009; 8(11): 987–997.
  113. Mattioli F, Stampatori C, Bellomi F, et al. Natalizumab efficacy on cognitive impairment in MS. Neurol Sci. 2011; 31(Suppl 3): 321–323.
  114. Marrie RA, Reingold S, Cohen J, et al. A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler. 2015; 21(3): 342–349.
  115. Minden SL, Feinstein A, Kalb RC, et al. Guideline Development Subcommittee of the American Academy of Neurology. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014; 82(2): 174–181.
  116. Rybakowski J, Pużyński S, Wciórka J. Psychiatria. Vol 2. Elsevier Urban & Partner, Wrocław 2010: 305–375.
  117. Feinstein A, Pavisian B. Multiple sclerosis and suicide. Mult Scler. 2017; 23(7): 923–927.
  118. Brola W, Fudala M, Czernicki J. Wpływ depresji na jakość życia chorych ze stwardnieniem rozsianym. Rehabil Med. 2007; 11: 9–13.
  119. Pérez LP, González RS, Lázaro EB. Treatment of mood disorders in multiple sclerosis. Curr Treat Options Neurol. 2015; 17(1): 323.
  120. Turner AP, Alschuler KN, Hughes AJ, et al. Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder. Curr Neurol Neurosci Rep. 2016; 16(12): 106.
  121. Marrie RA, Patten SB, Tremlett H, et al. CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Sex differences in comorbidity at diagnosis of multiple sclerosis: a population-based study. Neurology. 2016; 86(14): 1279–1286.
  122. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007; 13(1): 67–72.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel. +48 58 320 94 94, faks +48 58 320 94 60, e-mail: viamedica@viamedica.pl